Purchase this article with an account.
Takayuki Koike; Effect of intravitreal ranibizumab injection on eyes with refractory diabetic macular edema after sub-Tenon capsule triamcinolone acetonide injection. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1752.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the effect of intravitreal ranibizumab (IVR) on refractory diabetic macular edema (DME) after sub-Tenon capsule triamcinolone acetonide (STTA) injection.
This was a retrospective review of the medical records of 14 eyes of 11 patients with refractory DME after STTA. All eyes received intravitreal IVR between March 2014 and July 2014. The main outcome measurements were the best-corrected visual acuity (BCVA) and central macular thickness (CMT) measured by optical coherence tomography (OCT) before and after IVR. The followed-up period was three months. The statistical analyses were performed by paired t tests. A P<0.05 was considered significant.
The mean age was 64.8±12.4 years. Two eyes (14.2%) were pseudophakic eyes, 9 eyes (64.3%) had a history of pan-retinal photocoagulation, 4 eyes (28.5%) had partial photocoagulation, 10 eyes (71.4%) had microaneurysm photocoagulation, 2 eyes (14.2%) had subthreshold micropulse diode laser photocoagulation, and one eye (7.1%) had vitrectomy before the IVR. The mean BCVA was 0.382±0.20 logMAR units before STTA and 0.432±0.30 logMAR unit after STTA(P=0.5158). The mean BCVA was 0.408±0.29 logMAR units before and 0.354±0.22 logMAR units after the IVR (P=0.1285). The mean CMT was 526.20±90.57μm before STTA and 563.41±188.17 μm after STTA (P=0.6373). The mean CMT was 560.57±182.13 μm before IVR and 424.85±128.97μm after IVR (P=0.0222).
IVR can be a therapeutic option for refractory DME after STTA injection.
This PDF is available to Subscribers Only